Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 61 Carcinoma, Renal Cell 39 Neoplasm Metastasis 38 Neoplasms 24 Kidney Neoplasms 20 Neuroendocrine Tumors 19 Recurrence 16 Prostatic Neoplasms 15 Head and Neck Neoplasms 13 Tuberous Sclerosis 12 Triple Negative Breast Neoplasms 12 Lymphoma, Mantle-Cell 11 Hodgkin Disease 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 10 Lymphoma, Large B-Cell, Diffuse 10 Lymphoma 10 Colorectal Neoplasms 10 Waldenstrom Macroglobulinemia 9 Stomach Neoplasms 9 Multiple Myeloma 9 Leukemia, Lymphocytic, Chronic, B-Cell 9 Glioma 9 Glioblastoma 9 Brain Neoplasms 9 Sarcoma 8 Pancreatic Neoplasms 8 Melanoma 8 Lymphoma, Follicular 8 Lung Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8

Interventions

Drug Therapy 2 Blood Specimen Collection 2 ribociclib 1 pembrolizumab 1 palbociclib 1 epacadostat 1 bosutinib 1 amrubicin 1 Tumor Burden 1 Radiotherapy 1 Radiosurgery 1 Radiation 1 Quality of Life 1 Proton Therapy 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Immunotherapy 1 Histocompatibility Testing 1 Fluorodeoxyglucose F18 1 FAPI-46 1 Everolimus 1 Erlotinib Hydrochloride 1 Cisplatin 1 Bevacizumab 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Thymus Neoplasms × Everolimus × Clear all

NCT05918302 2026-05-12

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡